Hanneke V. L.
- Country
- The Netherlands
- Department
- Medical Oncology
Research Overview
- Phase III Randomized Trial of AZD0901 with Capecitabine ± Rilvegostomig in First‑Line Claudin‑18.2‑Positive HER2‑Negative Advanced Gastric, GEJ or Esophageal Adenocarcinoma
- Evaluation of AZD5863 and Tocilizumab in Advanced or Metastatic Solid Tumors: A Phase I/II Dose Escalation and Expansion Study
- Phase II Multicenter Randomized Trial of Neoadjuvant Chemotherapy and Chemoradiotherapy Regimens in Resectable Gastric Adenocarcinoma: Docetaxel, Capecitabine, Paclitaxel, Oxaliplatin, Carboplatin
Data & Insights
Has run more than one trial at 81 of 201 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating esophageal squamous cell carcinoma and gastroesophageal junction cancers, with particular focus on advanced therapeutic approaches.
- Upper GI tract malignancies
- Metastatic gastrointestinal cancers
- Esophageal cancer treatments
The investigator explores combination therapies involving chemoradiation and immunotherapy agents.
Immunotherapy Research
Active in developing immune checkpoint inhibitor therapies, particularly focusing on PD-1 inhibition approaches and novel immunotherapeutic combinations.
- Checkpoint inhibitor treatments
- TGF-β pathway targeting
- Tumor microenvironment studies
The investigator evaluates immune response markers and treatment efficacy in advanced cancers.
Precision Oncology
Focuses on biomarker-driven treatment approaches, particularly in dMMR (mismatch repair deficient) gastrointestinal cancers.
- Molecular profiling in GI cancers
- Targeted therapy combinations
- Treatment response assessment
The investigator studies personalized treatment strategies and innovative drug combinations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.